AI-discovered drug enters Phase II trial, first patients in US and China dosed
The drug has been tested in New Zealand and China and found to be safe.
In a recent press release, Insilico Medicine, the company that developed the drug, announced that it had entered Phase II of clinical trials and given its first dose to patients. The trials will take place at several sites in China and the US. 60 patients with Idiopathic pulmonary fibrosis (IPF) will be involved.
It is now common knowledge that \”Generative Artificial Intelligence\” refers to bots capable of performing tasks such as having human-like conversation or creating images or art. Insilico Medicine, based in Hong Kong and New York, has been using this technology to find therapies for crippling diseases for many years.
Source:
https://interestingengineering.com/health/ai-discovered-drug-phase-ii-trials
